Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
August 06, 2024 08:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap
July 24, 2024 08:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative...
Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap
July 02, 2024 08:00 ET
|
Annovis Bio, Inc.
Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population. Parkinson’s patients with substantial cognitive decline exhibited a...
Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap
June 27, 2024 08:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients
June 11, 2024 08:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for...
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast
June 05, 2024 08:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
Alzheimer’s Disease Diagnostics & Treatment Market Revenues to Reach US$11.9 Billion by 2030 - Market Size, Share, Forecasts, & Trends Analysis Report by Persistence Market Research
January 17, 2024 05:00 ET
|
Persistence Market Research
New York, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Market Size & Overview: The global market for Alzheimer's disease diagnostics and treatment is projected to experience a compound annual growth rate...
Vyant Bio Announces Adjournment of Special Meeting of Stockholders
September 20, 2023 13:00 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT), today announced that its special meeting of stockholders on September 20, 2023 (the...
Enhancing Care: Expansion of Alpers Disease Treatment Market Size On its Path to US$ 1.90 Billion by 2030, at a 4.57% of CAGR.
June 07, 2023 09:13 ET
|
Zion Market Research
Houston, TX, June 07, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “Alpers Disease Treatment Market By Diagnosis (Molecular Genetic Testing, Laboratory...
NRG Therapeutics Appoints Dr Jonathan Savidge as Independent Chair
April 26, 2023 04:00 ET
|
NRG Therapeutics Limited
STEVENAGE, United Kingdom, April 26, 2023 (GLOBE NEWSWIRE) -- NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has...